Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech buyouts.

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Oct 10, 2022 2:29pm

174 Views

Post# 35015942

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Biotech buyouts.

Could AN not going fwd with Pela reflect that they've been told by Oncy and their prospective acquiring company that they aren't going to have the chance? Could Oncy be tidying up things, as perhaps a deal in principle has been reached? Just thinking out loud.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"